Prognostic significance of FDG-PET in relapsed or refractory classical hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 11, 2011, Pages 1646-1652

  Smeltzer, Jacob P ^a   Cashen, Amanda F ^a   Zhang, Qin ^a   Homb, Andrew ^b   Dehdashti, Farrokh ^b   Abboud, Camille N ^a   DiPersio, John F ^a   Stockerl Goldstein, Keith E ^a   Uy, Geoffrey L ^a   Vij, Ravi ^a   Westervelt, Peter ^a   Bartlett, Nancy L ^a   Fehniger, Todd A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous stem cell transplantation; Classical Hodgkin lymphoma; FDG PET; Prognosis

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; VINBLASTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SALVAGE THERAPY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 80054859358     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.04.011     Document Type: Article

References (24)

1. Bartlett N.L. Modern treatment of Hodgkin lymphoma. Curr Opin Hematol 2008, 15:408-414.
2. Bierman P.J., Anderson J.R., Freeman M.B., et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996, 7:151-156.
3. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
4. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359:2065-2071.
5. Cashen A.F., Bartlett N.L. Therapy of relapsed Hodgkin lymphoma. Blood Rev 2007, 21:233-243.
6. Bierman P.J., Bagin R.G., Jagannath S., et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993, 4:767-773.
7. Brice P., Bouabdallah R., Moreau P., et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1997, 20:21-26.
8. Czyz J., Dziadziuszko R., Knopinska-Postuszuy W., et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004, 15:1222-1230.
9. Sureda A., Constans M., Iriondo A., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005, 16:625-633.
10. Sirohi B., Cunningham D., Powles R., et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008, 19:1312-1319.
11. Gallamini A., Hutchings M., Rigacci L., et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752.
12. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
13. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007, 25:571-578.
14. Bierman P.J., Lynch J.C., Bociek R.G., et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002, 13:1370-1377.
15. Josting A., Franklin J., May M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002, 20:221-230.
16. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616-623.
17. Castagna L., Bramanti S., Balzarotti M., et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009, 145:369-372.
18. Jabbour E., Hosing C., Ayers G., et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007, 109:2481-2489.
19. Moskowitz A.J., Yahalom J., Kewalramani T., et al. Pre-transplant functional imaging predicts outcome following autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. Blood 2010, 116:4934-4937.
20. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003, 102:53-59.
21. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1065-1072.
22. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. Normalization of FDG-PET Pre-ASCT with additional non-cross resistant chemotherapy improves EFS in patients with relapsed and primary refractory Hodgkin lymphoma-Memorial Sloan Kettering Protocol 04-047. Blood 2008, 112:A775.
23. Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma. ClinicalTirals.gov identifier: NCT01207921. Available at Accessed January 2011. http://clinicaltrials.gov/.
24. A phase 3 study of brentuximab vedotin (SGN-35) for prevention of Hodgkin lymphoma progression (The AETHERA Trial). ClinicalTrials.gov identifier: NCT01100502. Available at Accessed September 2010. http://clinicaltrials.gov/.